Clinical trials: Metastatic Colorectal Cancer (MCRC)
Metastatic Colorectal Cancer
A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice
This study is a multi-centre retrospective observational research study which will be conducted in UK centres with specialised liver surgical services.
- Trial name
- RESECT (NCT01460745)
- Where
- 5 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Cancer with Hepatic Metastases
TATE and KN046 in MCRC
A single-arm, multicenter, Phase IIA study of Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization (TATE) and KN046 (recombinant humanized anti-PD-L1/CTLA-4 bispecific single-domain antibody Fc…
- Trial name
- NCT06834399
- Testing
- KN046 （PD-L1/CTLA4 BsAb）, TATE：Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Zhejiang Raygene Pharmaceuticals Co., Ltd
Colon Cancer
Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer
This is a multicenter, two-stage trial with the goal of evaluating up to 100 subjects. This trial will be performed to initiate identification of a safe and effective dose of twice-weekly, subcutaneous rNAPc2 for the second-line…
- Trial name
- NCT00443573
- Testing
- recombinant nematode anticoagulant protein c2 (rNAPc2)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- ARCA Biopharma, Inc.
Metastatic Colorectal Cancer
A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland
Metastatic colorectal cancer or mCRC is a cancer that starts in the parts of the large intestine (the colon or rectum) and has already spread to other parts of the body.
- Trial name
- NCT07623174
- Testing
- No intervention
- Where
- 10 sites in Poland
- Volunteers
- 110 people
- Sponsor
- Takeda
Metastatic Colorectal Cancer (CRC)
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT06825624
- Testing
- HS-20093, Bevacizumab, 5-FU
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Hansoh BioMedical R&D Company
Ras-mutated Metastatic Colorectal Cancer, mCRC
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs.
- Conditions
- Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer
- Trial name
- NCT07446322
- Testing
- Bevacizumab, FOLFIRI, Pelareorep
- Where
- 19 sites in United States
- Volunteers
- 60 people
- Sponsor
- Oncolytics Biotech
Metastatic Colorectal Cancer (mCRC)
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
This study is a phase Ⅱ, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with Irinotecan and SG001 in Patients with Metastatic Colorectal Cancer…
- Trial name
- NCT06089330
- Testing
- JMT101, SG001, Irinotecan
- Volunteers
- 102 people
- Sponsor
- Shanghai JMT-Bio Inc.
Cancer, Colon Cancer
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
This is a multi-center, open-label, randomized, phase 2, two-arm clinical trial to be conducted in the United States. Approximately 210 eligible KRAS wild-type expressing metastatic colorectal cancer subjects who have failed…
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Metastatic Cancer
- Trial name
- NCT00418938
- Testing
- Panitumumab, Bevacizumab, Leucovorin
- Volunteers
- 266 people
- Sponsor
- Amgen
Metastatic Colorectal Cancer
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
A post marketing surveillance, prospective study to collect safety information from 250 subjects with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type metastatic colorectal cancer treated with Erbitux as final…
- Trial name
- NCT01134640
- Where
- 15 sites in Taiwan
- Volunteers
- 286 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Metastatic Colorectal Cancer (mCRC)
An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions
This is an observational study using data that has been collected from participants who received their usual treatments. Metastatic colorectal cancer (mCRC) is a cancer of the colon (large bowel) or the rectum (lowest part of the…
- Trial name
- STAR-T (NCT05839951)
- Testing
- Regorafenib (BAY73-4506, Stivarga®), TAS-102 (trifluridine and tipiracil, Lonsurf®), Bevacizumab
- Where
- United States
- Volunteers
- 818 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer
Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR Monoclonal antibody（SCT200）in patients with wild-type RAS and BRAF mCRC treated with fluorouracil, oxaliplatin and irinotecan after failure…
- Trial name
- NCT03405272
- Testing
- Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
- Where
- 21 sites in China
- Volunteers
- 110 people
- Sponsor
- Sinocelltech Ltd.
Metastatic Colorectal Cancer
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
This Study is in two parts, the first part is to make sure that combining a potential new treatment, cediranib (AZD2171), with a standard treatment (FOLFOX) for metastatic colorectal cancer is safe.
- Trial name
- NCT00494221
- Testing
- AZD2171, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- 2 sites in Japan
- Volunteers
- 172 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer
A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
The primary objective of this study is to demonstrate equivalence of pharmacokinetic properties, and comparability of safety and immunogenicity parameters of RPH-030 and Vectibix® following a single (first) intravenous…
- Trial name
- NCT07543744
- Testing
- RPH-030, Vectibix®, Irinotecan
- Where
- 26 sites in Russia
- Volunteers
- 180 people
- Sponsor
- R-Pharm
Metastatic Colorectal Cancer
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.
- Trial name
- ARC-9 (NCT04660812)
- Testing
- AB680, Etrumadenant, Zimberelimab
- Where
- 44 sites in United States, France and 4 more
- Volunteers
- 227 people
- Sponsor
- Arcus Biosciences, Inc.
Metastatic Colorectal Cancer
ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line
This is a national, multicentric, prospective, observational trial. The decision to prescribe FOLFOX or FOLFIRI plus panitumumab or FOLFOX or FOLFIRI plus cetuximab must have been freely taken by the clinician prior to the study…
- Trial name
- SILQ (NCT02624895)
- Where
- 31 sites in Italy
- Volunteers
- 296 people
- Sponsor
- Amgen
Metastatic Colorectal Cancer
An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to examine the correlation between UGT1A1 genotypes and the efficacy of CPT-11 based regimens (FOLFIRI, CPT-11+S-1, CPT-11) for patients with metastatic colorectal cancer.
- Trial name
- NCT01039506
- Testing
- CPT-11 based regimens
- Where
- Japan
- Volunteers
- 1,376 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Metastatic Colorectal Cancer
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the clinical efficacy of Serplulimab (HLX10) in Combination With Bevacizumab and Chemotherapy (XELOX) Versus Placebo in Combination…
- Trial name
- NCT04547166
- Testing
- HLX10, HLX04、
- Where
- 5 sites in China, Japan
- Volunteers
- 568 people
- Sponsor
- Shanghai Henlius Biotech
Colorectal Cancer
A Phase Ib Study of Fruquintinib in 3rd Line mCRC
Fruquintinib is a novel oral small molecule compound discovered and developed by Hutchison MediPharma that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent…
- Trial name
- NCT01975077
- Testing
- fruquintinib
- Where
- 2 sites in China
- Volunteers
- 62 people
- Sponsor
- Hutchison Medipharma Limited
Colorectal Cancer
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)
This will be a randomized, open-label, multicenter, Phase II study with primary objectives to assess whether expression of select chemotherapy markers is associated with progression-free survival (PFS) in participants treated…
- Trial name
- MAVERICC (NCT01374425)
- Testing
- 5-Fluorouracil, Bevacizumab, Irinotecan
- Where
- 79 sites in United States, Canada and 5 more
- Volunteers
- 376 people
- Sponsor
- Genentech, Inc.
Metastatic Colorectal Cancer
A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients
The purpose of this study was to assess whether the progression free survival (PFS) time with FOLFOX-4 plus cetuximab is longer than that with FOLFOX-4 alone as first-line treatment for mCRC in Chinese subjects with RAS wild-type…
- Trial name
- TAILOR (NCT01228734)
- Testing
- Cetuximab, Oxaliplatin, Folinic Acid
- Where
- 25 sites in China
- Volunteers
- 553 people
- Sponsor
- Merck KGaA, Darmstadt, Germany